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Health Organization predicts that this 
figure may exceed 100 million by the year 
2050 as life expectancies increase.[7] While 
these conditions are devastating with 
regard to patient suffering and impacts on 
family members and caregivers, neurolog-
ical amyloidoses are also responsible for 
more than USD 500 billion in worldwide 
annual costs.[7] Research groups across 
scientific disciplines have therefore inves-
tigated strategies to better understand and 
interfere with the transition from soluble 
monomeric proteins and peptides into 
soluble oligomers and, eventually, into 
insoluble amyloid fibrils and plaques that 
are hallmarks of several neurodegenera-
tive diseases.[8,9]
Amyloid-forming proteins often 
undergo an aggregation process analogous 
to crystal formation where the generation 
of a “seed” is the rate-limiting step for the 
assembly of a large ordered structure.[10,11] 
Treatments that are currently in clinical 
trial target these seeds and their precur-
sors in order to redirect or disrupt down-
stream aggregate formation at an early 
stage before irreversible nerve cell damage occurs.[12] Addition-
ally, there is evidence that the size, shape, and concentration 
of oligomeric amyloid aggregates determine their toxicity to 
neurons,[13,14] and patients with certain amyloidoses have ele-
vated counts of these oligomeric species in their cerebrospinal 
fluid (CSF).[15,16] Findings like these suggest that soluble amy-
loid aggregates may be valuable biomarkers for predicting or 
monitoring disease progression and may also help to assess the 
efficacy of therapeutic intervention. There is thus a need for a 
characterization technique that provides a comprehensive pro-
file of the individual amyloid particles in bodily fluids like CSF, 
blood, tears, saliva, or urine.[17,18]
While a range of techniques is currently being used to charac-
terize amyloids and their aggregation processes (Table 2), amy-
loid samples remain extremely difficult to analyze and none of 
the established techniques meets all demands of an ideal anal-
ysis method as outlined in Table 3.[19,20,25] For instance, amyloid 
aggregates are challenging analytes to characterize because they 
are heterogeneous in size and structure, they rearrange, inter-
change dynamically and grow over time, and they adhere to 
various surfaces including tubing and microvials.[26,27] Methods 
attempting to characterize ensembles of these heterogeneous 
Aggregates of misfolded proteins are associated with several devastating neu-
rodegenerative diseases. These so-called amyloids are therefore explored as 
biomarkers for the diagnosis of dementia and other disorders, as well as for 
monitoring disease progression and assessment of the efficacy of therapeutic 
interventions. Quantification and characterization of amyloids as biomarkers 
is particularly demanding because the same amyloid-forming protein can 
exist in different states of assembly, ranging from nanometer-sized mono-
mers to micrometer-long fibrils that interchange dynamically both in vivo and 
in samples from body fluids ex vivo. Soluble oligomeric amyloid aggregates, 
in particular, are associated with neurotoxic effects, and their molecular 
organization, size, and shape appear to determine their toxicity. This concept 
article proposes that the emerging field of nanopore-based analytics on a 
single molecule and single aggregate level holds the potential to account for 
the heterogeneity of amyloid samples and to characterize these particles—
rapidly, label-free, and in aqueous solution—with regard to their size, shape, 
and abundance. The article describes the concept of nanopore-based resis-
tive pulse sensing, reviews previous work in amyloid analysis, and discusses 
limitations and challenges that will need to be overcome to realize the full 
potential of amyloid characterization on a single-particle level.
Amyloid Aggregates
1. Introduction
Neurodegenerative disorders like Alzheimer’s disease and Par-
kinson’s disease, as well as other medical conditions like Type II 
diabetes, are associated with the presence and activity of toxic 
protein aggregates known as amyloids (Table 1).[1–6] The inci-
dence, or probability of occurrence, of many of these diseases 
increases with age.[5] Today, more than 30 million people world-
wide suffer from dementias linked to amyloids, and the World 
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aggregates obscure potentially important physical differences 
between individual macromolecular assemblies.[28] Conversely, 
techniques that label or chemically modify individual amyloids 
vary in their sensitivity and specificity to different morphologies 
or chemical structures and the modification itself may alter the 
sample.[29] Long and extensive sample preparation processes can 
bias amyloid populations toward stable species and may destroy 
potentially important transient complexes.[22] Nonetheless, cur-
rent approaches to characterize amyloids provide a range of rel-
evant parameters of amyloid aggregates. For instance, methods 
like transmission electron microscopy (TEM), atomic force 
microscopy (AFM), and mass spectrometry (MS) create “mac-
romolecular snapshots,” providing structural information about 
proteins and aggregates at a single time point.[20] Other tech-
niques using fluorescent dyes, tracer molecules such as 18F-flor-
betapir, or fluorescently labeled antibodies track aggregation pro-
cesses in vivo or in vitro to probe the dynamics and formation 
rates of different complexes.[30] Some methods focus on defining 
and detecting amyloid biomarkers that indicate disease predis-
position or progression.[15] Sometimes, researchers perform var-
ious analysis approaches in parallel in order to determine struc-
tural and chemical characteristics of an amyloid sample, though 
such combinations often require significant financial and tech-
nical resources as well as expertise. An ideal technique for amy-
loid characterization would combine these functionalities to 
provide rich, rapid, and robust information about single amyloid 
particles in high-throughput and in a clinical setting without the 
need for expensive equipment or technical expertise (Table 3).
One emerging technique that may meet several of these 
demands is resistive pulse-based nanopore sensing, as it is 
capable of characterizing individual unlabeled particles in 
aqueous solution. The method was originally developed in the 
late 1940s for applications on the microscale such as counting 
and characterizing biological cells.[31–33] Resistive pulse experi-
ments have now made it possible to probe nanoscale analytes 
including small molecules,[34,35] metal ions,[36] polynucleo-
tides,[37] nanoparticles,[38,39] proteins,[40–43] and amyloids.[42,44–56] 
The application of resistive pulse sensing to protein characteri-
zation emerged less than 15 years ago and is not as developed 
as the established methods listed in Table 2, but it combines 
attractive capabilities that make it a potentially powerful tool for 
studying amyloids. Some of these benefits, such as the char-
acterization of shapes, volumes, diffusion coefficients, and 
electrical and mechanical properties of individual proteins and 
protein complexes, are appealing for fundamental biophysical 
studies. Other advantages, including the ability to extract resis-
tive pulses from single unlabeled molecules and to perform 
analyses of those resistive pulses in real time, may be clinically 
useful.[57] This article focuses specifically on the application of 
resistive pulse sensing to amyloid-related protein analytes and 
discusses the concepts and challenges of this application.
2. Principles of Resistive Pulse Sensing
The concept of resistive pulse sensing traces back to the invention 
of the Coulter counter for blood cells.[58] Briefly, if two electrolyte-
filled reservoirs are connected by a small channel, a difference in 
electrical potential between the two reservoirs generates a current 
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Table 1. Peptides and proteins that form amyloid aggregates in human disease. Several of these amyloids have yet to be thoroughly characterized 
with respect to structure.
Name of peptide or protein Number of 
amino acidsa)
Secondary structureb) Associated diseases Relative global 
prevalencec)
Number of biomarker 
publicationsd)
Amyloid-β peptide (Aβ) 37–43 Intrinsically disordered Alzheimer’s disease
Hereditary cerebral hemorrhage with amyloidosis
Common 1284
α-Synuclein (α-Syn) 140 Intrinsically disordered Parkinson’s disease (with/without dementia)
Dementia with Lewy bodies
Multiple system atrophy
Common 139
Prion protein (PrP) 208 Intrinsically disordered 
(1–102), all α-helix,  
prion-like (103–208)
Creutzfeldt-Jakob disease
Fatal insomnia
Gerstmann-Sträussler-Scheinker disease
Huntington disease–like 1
Spongiform encephalopathy
New variant Creutzfeldt-Jakob disease
Kuru
Hereditary sensory and autonomic neuropathy
Very rare 26
Microtubule-associated  
protein tau (τ)
352–441 Intrinsically disordered Alzheimer’s disease
Pick disease
Progressive supranuclear palsy
Corticobasal degeneration
Frontotemporal dementia w parkinsonism linked to chr17
Argyrophilic grain disease
Tangle predominant dementia
Guam Parkinson dementia complex
Frontotemporal lobar degeneration
Chronic traumatic encephalopathy
Ganglioglioma
Meningioangiomatosis
Subacute sclerosing panencephalitis
Lead encephalopathy
Tuberous sclerosis
Hallervorden-Spatz disease
Lipofuscinosis
Common 1018
Huntingtin exon 1 ≈103–187 Intrinsically disordered Huntington disease Moderate 15
Abri peptide 34 Intrinsically disordered Familial British dementia Very rare 0
Adan peptide 34 Intrinsically disordered Familial Danish dementia Very rare 0
Fragments of immunoglobulin 
light chains
≈100 All β-sheet, Ig-like Light-chain amyloidosis Rare 3
Fragments of immunoglobulin 
heavy chains
≈190 All β-sheet, Ig-like Heavy-chain amyloidosis (renal) Rare 0
Full or N-term fragments of 
serum amyloid A protein (SAA)
45–104 All-α, SAA-like four-helix 
bundle
AA amyloidosis Rare 452
Transthyretin (TTR) 127 All β-sheet, prealbumin-like Senile systemic amyloiosis
Familial amyloidotic polyneuropathy
Familial amyloid cardiomyopathy
Leptomeningeal amyloidosis
Rare 53
β2-microglobulin (β2-m) 99 All β-sheet, Ig-like Dialysis-related amyloidosis
Hereditary visceral amyloidosis
Rare 8
N-term fragments  
of apolipoprotein A-I (ApoAI)
69–100 Intrinsically disordered ApoAI amyloidosis Rare 14
C-term extended  
apolipoprotein A-II (ApoAII)
98 Unknown ApoAII amyloidosis (renal) Rare 2
N-term fragments of apolipopro-
tein A-IV (ApoAIV)
≈70 Unknown ApoAIV amyloidosis Rare 3
Apolipoprotein C-II (ApoCII) 79 All α-helix, unknown fold ApoCII amyloidosis (renal) Rare 0
Apolipoprotein C-III (ApoCIII) 79 All α-helix, unknown fold ApoCIII amyloidosis (renal) Rare 3
Fragments of gelsolin 53 or 71 Intrinsically disordered Familial amyloidosis, Finnish type Very rare 6
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through the channel. This ionic current is constant at a constant 
potential difference, but when an insulating particle passes from 
one reservoir to the other through the channel (i.e., through the 
sensing volume), it transiently displaces conducting electrolyte 
and reduces the current to produce a resistive pulse.[38,59,60] With 
regard to the other macromolecules in solution, the method can 
also be thought of as a transient purification, as it interrogates 
one particle at a time from bulk solution. Due to high electric 
field and concomitant fast electrophoretic motion of particles in 
the pore, the probability of finding two macromolecules in the 
small sensing volume at the same time is very low, especially 
when the average duration between particle capture is at least 
100-fold longer than the average duration of the resistive pulses. 
In scenarios where particle concentrations are relatively high 
(≈1 × 10−3 m or greater) and each particle dwells within the pore 
for a relatively long duration (≈1 ms or greater), the probability of 
multiple-occupancy events increases and may lead to rare events 
that must be excluded from analysis.[61] For protein analysis by 
resistive pulse sensing, the protein concentrations are, however, 
typically in the micromolar range or below and the dwell times 
are typically shorter than 1 ms. “Continuous” resistive-pulses, 
like those generated when long strands of nucleic acids pass 
end-to-end through a sensing volume, have a particular set of 
intricacies that are reviewed elsewhere.[62–67] Here, we highlight 
the resistive pulses produced by discrete particles, which typically 
have lengths shorter than the length of the nanopore, as these 
are relevant for the sensing and characterization of amyloid 
oligomers and short protofibrils.
Small 2018, 14, 1802412
Name of peptide or protein Number of 
amino acidsa)
Secondary structureb) Associated diseases Relative global 
prevalencec)
Number of biomarker 
publicationsd)
Lysozyme (LYS) 130 α-helix + β-sheet,  
lysozyme fold
Lysozyme amyloidosis (visceral) Rare 8
Fragments of fibrinogen α-chain 45–81 Unknown Fibrinogin amyloidosis (renal) Rare 27
N-term truncated cystatin C 110 α-helix + β-sheet, 
cystatin-like
Hereditary cerebral hemorrhage with amyloidosis, 
Icelandic type
Very rare 21
Islet amyloid polypeptide (IAPP) 37 Intrinsically disordered Type II diabetes
Insulinoma
Common 8
Calcitonin 32 Intrinsically disordered Medullary carcinoma of the thyroid Moderate 0
Atrial natriuretic factor (ANF) 28 Intrinsically disordered Atrial amyloidosis Common 0
N-term fragments of prolactin 
(PRL)
34 Unknown Pituitary prolactinoma Moderate 2
Insulin (30 + 21) All α-helix, insulin-like Injection-localized amyloidosis Very rare 61
Medin 50 Intrinsically disordered Aortic medial amyloidosis Rare 0
Lactotransferrin (lactoferrin) 691 α-helix + β-sheet,  
periplasmic binding  
protein-like II
Gelatinous drop-like corneal dystrophy Rare 1
Odontogenic ameloblast-
associated protein (ODAM)
110–118 Unknown Calcifying epithelial odontogenic tumors Rare 1
Pulmonary surfactant-associated 
protein (SP-C)
35 All α-helix, transmembrane 
helical fragment
Pulmonary alveolar proteinosis Rare 1
Leukocyte cell-derived 
chemotaxin-2
133 All β-sheet, barrel-sandwich 
hybrid
Renal amyloidosis Rare 0
Galectin 7 (Gal-7) 136 All β-sheet, concanavalin 
A-like lectins
Lichen amyloidosis, macular amyloidosis Rare 0
Corneodesmosin (CDSN) 167, 182, 206 Intrinsically disordered Hypotrichosis simplex of the scalp Very rare 0
C-term fragments  
of kerato-epithelin (βig-h3)
50–200 Unknown Lattice corneal dystrophy, type 1
Lattice corneal dystrophy, type 3A
Lattice corneal dystrophy, Avellino type
Common 0
Semenogelin-1 (SGI) 439 Unknown Seminal vesicle amyloidosis Moderate 0
Protein S100A8/A9 92 or 113 All α-helix, EF hand-like Prostate cancer Common 8
Enfuvirtide 36 Unknown Injection-localized amyloidosis Very rare 0
a)The total number of amino acids corresponds to the protein or peptide species that forms amyloids; b)Secondary structures are determined from the Structural 
Classification of Proteins (SCOP) database; c)Estimates of relative global prevalence estimates are approximate and binned as follows: “Very rare” corresponds to less 
than 10 000 cases globally, “Rare” corresponds to a maximum of 100 000 cases globally, “Moderate” represents a maximum of one million cases globally, and “Common” 
represents more than one million cases globally; d)Numbers of publications discussing each protein or peptide as potential biomarkers were gathered via Web of 
Science using an advanced search to find articles containing the respective protein or peptide name AND the word “biomarker” AND the word “amyloid”; Adapted with 
permission.[2] Copyright 2017, Annual Reviews.
Table 1. Continued.
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For resistive pulse sensing at any scale, sensing volumes 
must be appropriately sized to their target analyte.[68] A particle 
will not produce a detectable signal if its volume is more than 
1000-fold smaller than the sensing volume, and it will not trans-
locate through a sensing volume that it cannot enter due to steric 
constraints. Particles that do not conform to these size restric-
tions can still provide indirect information about the system,[69] 
but they cannot be analyzed directly within the sensing volume. 
If the sensing volume is sufficiently large to allow a nonspherical 
particle to rotate relatively freely, the particle will produce a 
unique resistive pulse signature that depends not only on its 
volume, but also on its shape and relative orientation to the 
electric field (Figure 1).[41,68] Rotations during transit through 
the pore cause fluctuations within the resistive pulse that 
originate from different orientations of a 3D shape in the 
electric field. The physical basis for this orientation dependence 
was first explored by Golibersuch[68] and others,[31,70] who found 
that rotations of disk-shaped red blood cells passing through a 
cylindrical channel generated characteristic resistive pulses with 
distinct minima and maxima. The minimum values (ΔIMIN) cor-
responded to the cell in its edgewise orientation relative to the 
channel axis, and the maximum values (ΔIMAX), which were 
about twofold greater in amplitude than the minimum, corre-
sponded to the cell in its crosswise orientation relative to the 
channel axis (Figure 1b). Fricke[71] and others[72] quantified these 
effects with a physical descriptor, the electrical shape factor γ, 
which depends on the particle’s ellipsoidal shape and orienta-
tion within a cylindrical sensing volume, and is directly propor-
tional to resistive pulse amplitude. The electrical shape factor is 
also valid on the nanoscale, though nanometer-sized proteins 
and particles rotate at a rate that is several orders of magnitude 
faster than cells and thus require high-bandwidth recording 
electronics and strategies like surface anchoring[40] to slow their 
rotation in order to fully resolve their characteristic fluctuations. 
Our group recently took advantage of these fluctuations in order 
to approximate the shape of an individual particle translocating 
through a nanopore.[41,73] Furthermore, we used the particle’s 
bias toward certain orientations during its transit through the 
strong electric field inside of the nanopore (several MV m−1) to 
estimate the net dipole moment of the particle. The most prob-
able speed at which the particle transitions between these orien-
tations is proportional to its bulk rotational diffusion coefficient, 
and the amount of time that a particle occupies the sensing 
volume, also referred to as its dwell or residence time, is a func-
tion of the particle’s lateral diffusion coefficient and is inversely 
proportional to its net charge. Measured simultaneously, these 
five parameters—shape, volume, charge, rotational diffusion 
coefficient, and dipole moment—define a high-content multi-
dimensional “fingerprint” of an unlabeled particle that helps to 
characterize, and discriminate between, particles in a mixture.[41]
Resistive pulse sensing can also probe the conformational 
variability of particles.[43,74,75] When a particle is sterically con-
strained within a small sensing volume, the resistive pulse asso-
ciated with that particle’s translocation provides information 
about the particle’s conformational variability.[43,74,75] In the case 
of proteins, this information appears as fluctuations in ampli-
tudes between multiple resistive pulses (Figure 1d) and has been 
attributed to differences in secondary structural composition 
(e.g., β-sheet to α-helix ratio).[43,74,75] Resistive pulse experiments, 
in principle, may also make it possible to monitor the interac-
tions of particles or amyloid-forming molecules with soluble 
species. For instance, our group used a nanopore to monitor 
immunoprecipitation and to determine the binding affinity of 
an antibody to the surface of a virus particle by relating resistive 
pulse amplitudes over time to the number of binding sites occu-
pied on the particle. In these approaches, each binding event 
increased the aggregate volume, and thus the magnitude of the 
resistive pulse, by a constant increment.[76–78] Likewise, Si and 
Aksimentiev showed that denatured proteins produce different 
resistive pulses than their native protein counterparts, and that 
the differences correspond to unfolding processes.[41,79] Each of 
these applications of resistive pulse sensing provides different 
information about individual particles in aqueous solution and 
about their time-dependent changes in response to various 
stimuli. Table 4 summarizes the attributes that nanopore-based 
analysis can bring to amyloid characterization.
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Table 3. Characteristics of an ideal next-generation method for characterizing amyloid aggregates and their precursors.
– Capability to characterize, quantify, and monitor amyloid monomers, amyloid oligomers, protofibrils, and fibrils on a single-molecule and single aggregate level.
– Rapid analysis within seconds and within aqueous solution.
– Label-free analysis method with minimal sample preparation such that the amyloid status of the sample remains unperturbed and representative of its status in the patient.
– Small sample volumes (microliters or smaller).
– Capability to characterize physical properties like 3D shape, volume, secondary structure, conformational change, dipole moment, and diffusion coefficients. Ideally 
refine the approach such that it may ultimately reveal the mass of individual amyloid particles and provide atomic-level structural information about these particles.
– Broadly accessible technique.
– High reproducibility between different users and measurement environments.
– High specificity to amyloid biomarker of interest.
– High—ideally single molecule—sensitivity to amyloid aggregates at extremely low concentrations.
– Low-cost instrumentation and operation.
– Capability to make measurements in a clinical environment with instant diagnostic value.
– Capability to detect amyloids in a range of bodily fluids like cerebrospinal fluid, tears, saliva, blood, or urine.
– Minimal technical expertise required for operation.
– Capability to detect post-translational modifications of amyloid-forming peptides and proteins such as phosphorylations or glycylations, etc.
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3. Amyloid Characterization with Biological 
Nanopores
Biological nanopores range from ion channels to assemblies of 
pore-forming toxins[80,81] and their biological function is to facili-
tate or regulate the passage of polar molecules, ions, or peptides 
across cell membranes.[82] With regard to resistive pulse 
sensing, biological nanopores are appealing as their sensing 
volumes are often defined with atomic precision and they can 
be produced in large quantities through bacteria fermentation 
or cell culture followed by purification.[83] Due to their extremely 
small sensing volumes in pore lumens with diameters smaller 
than 4 nm (Figure 2), biological nanopores are particularly well-
suited to sensing small analytes, including proteins smaller than 
30 kDa as well as single-stranded and double-stranded DNA or 
RNA.[84–86] Furthermore, several of these protein-based nanop-
ores can be engineered by site-directed mutagenesis to integrate 
desired properties such as specific binding sites or residues that 
modify the electrostatic landscape in the pore lumen.[34,87,88]
3.1. Resistive Pulses to Interrogate Enzymatic Cleavage 
of Amyloid-Forming Peptides
Two key research developments facilitated the nanoscale application 
of resistive pulse counting with biological nanopores: inhibiting the 
voltage-dependent nature of ion channel proteins,[35,89,90] and lim-
iting the rate at which biomolecules of interest transit the lumen of 
the pore.[91,92] These developments enabled seminal work by Bez-
rukov and Kasianowicz, who used the pore from α-toxin (Staphy-
lococcus aureus) to measure protonation rates and to discriminate 
between protons and deuterons.[89,90] Kasianowicz et al. were the 
first to demonstrate the detection of individual polynucleotide mole-
cules using the pore α-hemolysin,[93] and Bezrukov et al. showed 
that dwell times of certain polyethylene glycol (PEG) molecules 
were more than 1000-fold longer than values predicted by 1D diffu-
sion because the molecules reversibly bind within the nanopore;[91] 
a formal theory later proposed by Lubensky and Nelson helped to 
explain these polymer–pore interactions.[94] This body of research 
established biological nanopores as resistive pulse sensors, and bio-
logical nanopores have since made it possible to detect not only poly-
mers, but also small molecules,[61] and amyloid-forming peptides.
The first report of characterizing an amyloid-related peptide 
with biological nanopores focused on the amyloid-β (Aβ) pep-
tide segment Aβ10–20.[45] (Note here that Aβ refers to a peptide 
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Figure 1. Cartoons relating the passage of different particles through a 
sensing volume to resistive pulses for particles with different volume, 
shape, aggregation state, or conformational flexibility. a) An electrical 
potential applied across the pore creates a constant ionic current, and par-
ticles passing through the sensing volume produce resistive pulses pro-
portional to their volume. Reproduced with permission[58] U.S. Patent 
No. US2656508A, 1953. b) Translocation of spherical particles through 
cylindrical nanopores produces square-shaped resistive pulses, and the 
duration of translocation events is proportional to their electrophoretic 
mobility. Brownian rotation of nonspherical particles modulates the ionic 
current through the sensing volume depending on their orientation within 
the pore. The minimum (ΔIMIN) and maximum (ΔIMAX) blockade values 
can be used to estimate shape, dipole moment, and rotational diffusion 
coefficient of the particle. Reproduced with permission.[41] Copyright 2016, 
Macmillan Publishers Limited. c) Two or more particles bound together 
produce a larger resistive pulse (ΔIBOUND) than sequential translocation 
of individual particles (ΔIUNBOUND). The fraction of resistive pulses from 
bound to unbound particles is related to binding affinities. Reproduced 
with permission.[76] Copyright 2006, Wiley-VCH. Reproduced with permis-
sion.[78] Copyright 2006, Elsevier B.V. d) Variations in particle structure 
may be revealed when confined or compressed within a sensing volume 
depending on the conformational stability of the molecule or molecular 
complexes. Less-flexible particles (σSTIFF) produce resistive pulses with 
smaller amplitude fluctuations than flexible particles (σFLEX). Reproduced 
with permission.[43] Copyright 2017, American Chemical Society.
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involved in Alzheimer’s disease that typically contains between 
37 and 43 amino acids, and we denote the particular segment 
of Aβ using subscripted numbers.) By modifying the interior 
of an α-hemolysin pore to contain additional aromatic binding 
regions, Zhao et al. prolonged the residence times of Aβ10–20 
and other peptides rich in aromatic residues. They related resi-
dence times and resistive pulse amplitudes of the peptides to 
binding affinities within the nanopore, and demonstrated that 
nanopores could be used to determine the presence or absence 
of various small peptides in a mixture.[44] This setup also allowed 
Zhao et al. to monitor trypsin-catalyzed cleavage of Aβ10–20. 
Cleavage of proteins like amyloid precursor protein (APP) by 
β- and γ-secretases plays a role in amyloid formation and 
thereby possibly influences diseases like Alzheimer’s and Par-
kinson’s.[95] These results demonstrated that nanopores can 
provide information about the kinetics of enzymatic cleavage of 
amyloids without the need to label the amyloids.[44]
3.2. Interactions between Amyloid-Forming Peptides 
and Molecules That Modulate Aggregation
Experiments with biological nanopores can investigate interac-
tions between small molecules and amyloid-forming peptides. 
Wang et al. studied the influence of aggregation promotors 
like β-cyclodextrin and aggregation inhibitors like Congo red 
on the aggregation kinetics of Aβ. To this end, the authors 
followed aggregation over time by monitoring the frequencies 
of resistive pulses, which are related to particle concentration, 
and the amplitudes of resistive pulses, which are related to par-
ticle size.[46] A similar assay revealed the influence of copper 
(Cu2+) ions on the conformation of Aβ1–16 peptide and the rate 
at which it formed oligomers. Human Aβ1–16 had stronger and 
longer-lasting interactions with Cu2+ compared to the rat var-
iant of Aβ1–16, likely because of a single amino acid difference 
(human HIS-13 vs rat ARG-13).[96] Wang et al. proposed that 
HIS-13 plays a role in metal-induced aggregation and could 
therefore be a potential therapeutic target.[97] Information about 
aggregation behavior of specific peptide subsequences may 
be useful in the context of therapeutic approaches to inhibit 
aggregation, and it can reveal structure–function relation-
ships for the full-sequence peptide. For instance, the Aβ25–35 
peptide has a β-sheet structure and forms aggregates, but its 
inverted sequence Aβ35–25 takes on a random coil structure and 
does not exhibit neurotoxicity.[98] Hu et al. found that Aβ25–35 
produced large current blockages due to its extended β-sheets 
and its translocation events became less frequent with time, 
suggesting that it was aggregating into complexes too large 
to enter the sensing volume of the α-hemolysin nanopore.[52] 
Solutions of Aβ35–25, on the other hand, generated smaller and 
shorter blockage events than those of Aβ25–35, and frequen-
cies of Aβ35–25 translocation events were consistent over time, 
suggesting that the β-sheet motif could be detected using a 
nanopore and likely plays a role in aggregation.[52]
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Table 4. Unique attributes that make nanopore-based analyses attractive for the characterization of amyloid particles.
General to all nanopore designs
– Capability to characterize single molecules and individual molecular aggregates. This capability is an essential feature for heterogeneous amyloid particles that span a 
large range in aggregate diameters, lengths, and shapes and whose size and shape may determine their toxicity.
– The method isolates single particles transiently from a mixture and interrogates them one by one. This feature makes it possible to draw conclusions from an  
artifact-free signal that originates uniquely from the one particle under study until the particle exists the interrogation volume and makes room for the next particle.
– Method is solution-based, and therefore circumvents or reduces perturbations by drying or interactions with surfaces.
– First results are obtained within seconds after dispensing amyloid samples onto the nanopore chip therefore time-dependent changes of amyloid status may be  
minimized or can at least be monitored and accounted for.
– Characterization can yield rich information simultaneously from individual particles, including volume, shape, dipole moment, rotational diffusion coefficient, charge, 
and conformational variability of the amyloid.
– The approach is label-free making it possible to assess amyloid status without possible perturbation by labels.
– Nanopores offer one of the lowest cost and most accessible single-molecule characterization techniques. This technique is in the process of revolutionizing DNA and RNA 
sequencing in a broadly accessible, user-friendly, compact, and low-cost format that takes advantage of parallel recordings from hundreds of nanopores. If some of these 
benefits could be implemented in the context of nanopore-based amyloid analysis, then it may make longitudinal monitoring of an aging population over decades possible.
– Nanopore-based analysis requires extremely small sample volumes; microliters and even nanoliters may be sufficient. This capability may open up new strategies for 
sampling body fluids such as CSF that are less invasive than existing approaches.
– Analysis of experimental data from amyloid characterization can be automated and occur in real time during the translocation of individual amyloid particles through 
the nanopore. Amyloid status may thus be instantly updated, interpreted, and released.
– As the field progresses, atomic and molecular-scale simulations of amyloid translocations through nanopores combined with experimental and clinical data and 
machine learning approaches may reveal meaningful connections between the amyloid status and diagnostic and clinical significance. These developments could 
further strengthen and streamline analysis of amyloids and may make amyloid monitoring a routine part of medical testing.
Specific to biological nanopores
– Can detect monomers of amyloid-forming species and products of enzymatic cleavage.
– Site-directed mutagenesis of biological nanopores makes it possible to incorporate molecular groups that bind, or respond specifically, to amyloid-forming molecules.
Specific to synthetic nanopores
– Synthetic nanopore diameter and shape can, in principle, be adjusted to and optimized for various amyloid species of interest.
– Surface coatings of synthetic nanopores can bind or respond to amyloid-forming species.
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3.3. Investigations of Amyloid-Forming 
Peptides Other Than Aβ
Most detection and characterization of amy-
loids with biological nanopores has focused 
on the Aβ peptide. As Table 1 shows, there 
are more than 30 amyloid-forming pep-
tides or proteins that are associated with 
human disorders, including prion protein 
(PrP) in the spongiform encephalopathies, 
huntingtin protein in Huntington’s disease, 
and α-synuclein (α-Syn) in Parkinson’s dis-
ease.[5] One reason that Aβ has been pop-
ular in research with biological nanopores 
is its small (4.5 kDa) molecular weight; 
many other amyloid-forming proteins are 
too large in their natively folded conforma-
tion to fit through the small confines of a 
biological nanopore. Some proteins, like 
α-Syn, are natively unfolded and can pass 
through the nanopore as a single strand,[49] 
while large globular proteins can be dena-
tured in a solution of 5 m guanidinium HCl 
and passed through the sensing volume 
in a mostly unfolded state.[47] Jeremy Lee’s 
research group employed this denaturation 
strategy and reported distributions of cur-
rent blockades for different prion proteins, 
as well as for Aβ and α-Syn.[47,99–101] Despite 
these approaches, the large size of some 
amyloid-forming proteins or their aggregates 
remains a major challenge to their charac-
terization with biological pores, especially 
when the native structure of the protein or 
amyloid particle is of interest. At present, no 
biological pore can accommodate an intact 
amyloid oligomer with a diameter larger 
than 4 nm. Some research groups have 
begun to engineer protein-based nanopores 
with larger sizes than natural pores,[88,102,103] 
while others have chosen to fabricate and 
use synthetic nanopores in different sizes 
and materials.
4. Amyloid Detection and 
Characterization with Synthetic 
Nanopores
Synthetic nanopores with custom diameters 
in the range from 1 to 100 nm facilitate the 
detection and analysis of larger biomolecules 
including natively folded proteins[104,105] and 
double-stranded DNA.[106,107] Typically, these 
sensing volumes are fabricated by generating 
holes with nanometer-scale diameters in thin 
(less than 100 nm) insulating membranes 
(Figure 3). Manufacturing techniques for 
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Figure 2. Cross sections of biological nanopores used in resistive pulse sensing. These 
illustrations show the unique high-resolution structures and sizes of these proteins, which 
connect two electrolyte-filled chambers across a lipid membrane. As shown for α-hemolysin, 
protein pores insert into lipid bilayer membranes (gray) and conduct a constant ionic current 
if a constant voltage is applied across the membrane. Scale bars show the narrowest con-
striction of each sensing volume and were measured from high-resolution structures using 
Chimera software with the following codes from the protein data bank: α-hemolysin (7AHL), 
FraC (4TSY), MspA (1UUN), Phi29 Motor Protein (1JNB), α-aerolysin (5JZT), CsgG (4UV3), 
and ClyA (2WCD).
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nanopore formation include dielectric break-
down,[108] TEM drilling,[109] helium ion micro-
scope drilling,[110] capillary shrinking,[111] and 
gold particle heating,[112] while substrates 
range from silicon,[113] silica (glass),[114] sil-
icon nitride,[105] MoS2,[115] HfO2,[116] and gra-
phene.[117] Synthetic nanopores of all sizes 
and materials still suffer from two critical 
drawbacks: proteins tend to adhere to the 
nanopore substrate and hence clog the pore, 
or—when proteins do not adhere to the sub-
strate—they transit the nanopore too quickly 
such that the majority of them cannot be 
detected by conventional electrical recording 
equipment.[40,118]
4.1. Lipid Bilayer Coatings Allow Measurements 
of Amyloids with Synthetic Nanopores
In response to these problems, several 
research groups in the synthetic nanopore 
field have focused on creating antiadhesive 
coatings.[40,119] One such coating introduced 
by our group—fluid lipid bilayers—prevents 
unwanted adhesion and slows protein 
transit through the nanopore by anchoring 
proteins to activated lipids.[120] To this end, 
we coated a silicon nitride nanopore with a 
supported lipid bilayer in order to charac-
terize Aβ1–40 peptide in the first application 
of a synthetic nanopore to an amyloid-
related protein.[40,42] This work quantified 
the formation of four distinct Aβ1–40 aggre-
gates over the course of a 72 h aggregation 
period: spherical oligomers, short protofi-
brils, long protofibrils, and amyloid fibers. 
The event frequency of each species, which 
is a measure of their abundance, reflected 
the extent of aggregation; spherical oli-
gomers gradually became less frequent as 
they grew in size while resistive pulses from 
protofibrils and mature fibers increased in 
frequency over time.
Coatings derived from materials other 
than lipid bilayers can also reduce unwanted 
adhesion. Rui et al. investigated α-Syn 
aggregation using synthetic nanopores 
coated with polysorbate 20 (Tween 20). This 
work characterized four different oligomeric 
species, and investigated the impact of small 
unilamellar vesicles (SUVs) containing 
certain lipids on the rates of aggregation 
of α-Syn.[55] Similarly, Giamblanco et al. 
functionalized nanopores with polyethylene 
glycol (PEG-5k) chains in order to study 
the aggregation kinetics and fibril sizes of 
amyloid particles comprised of lysozyme 
and other model proteins.[56]
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Figure 3. Schematics showing examples of synthetic nanopore designs used for amyloid char-
acterization. a) Image of a silicon scaffold supporting a freestanding silicon nitride membrane, 
and cross section of a nanopore in a freestanding membrane with an antiadhesive coating. 
b) Glass capillary tubes can be locally heated and mechanically stretched to terminate in hollow 
tips with nanometer diameters. The terminal tips then act as a sensing volume that connects 
two electrolyte-filled reservoirs. Adapted under the terms and conditions of the Creative 
Commons Attribution 3.0 Unported Licence.[51] Copyright 2015, The Royal Society of Chemistry. 
c) Scanning electron microscopy (SEM) images of a membrane containing parallel nanochan-
nels used to connect two reservoirs. The membrane was functionalized with amyloid-forming 
peptides, and the ionic current through the membrane slowly declined as peptides aggregated 
and occluded the channels. Adapted with permission.[54] Copyright 2016, Elsevier.
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4.2. Model Proteins That Form Fibrils Demonstrate Assembly 
Processes in Nanopores
Because of difficulties with the preparation, analysis, or toxicity 
of amyloid samples,[26] several groups have chosen to investi-
gate proteins like lysozyme or bovine serum albumin (BSA) that 
readily aggregate into amyloid-like fibrils but are not necessarily 
pathogenic to humans. In an attempt to develop a system that 
relates a population of resistive pulse amplitudes and durations 
to a concentration profile of amyloid (proto)fibrils, Martyushenko 
et al. monitored the aggregation process of lysozyme into long 
fibrils using glass nanocapillaries.[51] The authors performed 
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Figure 4. Cartoons summarizing various approaches for the analysis of amyloid-forming peptides with nanopores. a) Biological nanopores have been 
used to investigate interactions of amyloid forming peptides with aggregation promotors or inhibitors as well as to evaluate conformational differences 
between peptides. Synthetic nanopores have determined size distributions of aggregates over time, by employing a variety of antiadhesive coatings. Both 
biological and synthetic pores have been used to determine aggregation rates of amyloids. b) Amyloid beta1–42 produces only short collision events in the 
presence of an aggregation promoter as the protein is sterically excluded from entering the pore, and generates small, short-lived events in the presence of 
an aggregation inhibitor. Adapted with permission.[46] Copyright 2011, American Chemical Society. c) As Aβ10–20 is enzymatically cleaved apart by trypsin, it 
produces smaller and shorter resistive pulses that correspond to the turnover rate and the length of the Aβ fragments. Adapted with permission.[44] Copy-
right 2009, American Chemical Society. d) Monitoring the formation of a-synuclein aggregates over the course of 96 h; aggregates can be grouped into four 
major phenotypes (O1, O2, O3, and O4). Adapted under the terms and conditions of the Creative Commons Attributions 4.0 License.[55] Copyright 2016, 
Macmillan Publishers Limited. e) Amyloid beta(1–40) undergoes a time-dependent aggregation process forming small spherical oligomers (SO), short 
protofibrils (SP), long protofibrils (LP), and finally mature fibrils (F) Each of these species can be detected, grouped, and characterized using a lipid bilayer 
coated synthetic nanopore. Adapted with permission.[42] Copyright 2012, American Chemical Society.
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the experiments at pH 2.0 in order to prevent adhesion to the 
glass substrate and determined a distribution of aggregates that 
they compared with results from simulations.[51] Balme et al. 
expanded upon this research with lysozyme fibrils and focused 
on the effects of protein adhesion to the surface of a silicon 
nitride nanopore; these authors mitigated adhesion by treating 
the nanopore with concentrated sulfuric acid directly before 
experiments. The authors then extracted distinct populations 
of lysozyme oligomers from the distribution of resistive pulse 
amplitudes and correlated those particular populations with indi-
vidual monomer additions.[53]
4.3. Investigations of Prion Protein with Synthetic Nanopores
Li et al. took advantage of the large volumes of synthetic nano-
pores to characterize and compare a range of commonly avail-
able proteins like BSA and IgG1 antibody as well as human 
PrP.[50] This report represented the first measurements of 
native PrP with a synthetic nanopore. The experiments were 
hampered by transient protein adhesion to the glass substrate, 
but nonetheless revealed differences in dwell times and pulse 
amplitudes between standard proteins and PrP; the authors 
related these differences to protein structure and aggregation 
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Table 5. Timeline of studies that characterized amyloid-forming peptides or proteins with nanopores.
Protein/peptide Title Nanopore 
style
Nanopore  
details
Unique aspect(s) Year Ref.
Amyloid-β (10–20) Real-time monitoring of peptide  
cleavage using a nanopore probe
Biological α-Hemolysin Monitored enzymatic rate indirectly 2009 [44]
Amyloid-β (10–20) Study of peptide transport through  
engineered protein channels
Biological α-Hemolysin Modified interior α-hemolysin nanopore to extend 
dwell times of peptides containing aromatic residues
2009 [45]
Amyloid-β (1–40) Controlling protein translocation  
through nanopores with bioinspired  
fluid walls
Synthetic Silicon nitride, 
lipid bilayer 
coated
Coated synthetic nanopores with lipid bilayers  
for the first time, and recorded the  
translocation of Aβ aggregates
2011 [40]
Amyloid-β (1–42) Nanopore analysis of β-amyloid  
peptide aggregation transition induced  
by small molecules
Biological α-Hemolysin Compared aggregation kinetics of Aβ in the  
presence of aggregation inhibitors and promotors
2011 [46]
Amyloid-β (1–40, 1–42), 
α-synuclein, prion protein 
(PrP) human and bovine
Nanopore analysis: An emerging  
technique for studying the folding  
and misfolding of proteins
Biological α-Hemolysin Investigated a large group of amyloid-forming 
proteins with a nanopore, denatured larger 
proteins to fit
2012 [47]
Amyloid-β (1–40) Single-particle characterization of Aβ 
oligomers in solution
Synthetic Silicon nitride, 
lipid bilayer 
coated
Monitored the aggregation of Aβ and classified  
four species of aggregates
2012 [42]
Amyloid-β (1–16), human 
and rat
Investigation of Cu2+ binding to human 
and rat amyloid fragments Aβ (1–16)  
with a protein nanopore
Biological α-Hemolysin Related interactions between peptides and  
metal ions to specific amino acid differences 
between peptide variants
2013 [48]
α-Synuclein Analysis of a single α-synuclein  
fibrillation by the interaction  
with a protein nanopore
Biological α-Hemolysin Analyzed α-synuclein with a protein nanopore, 
quantified aggregate-promoting interactions  
with lipid bilayers
2013 [49]
Prion protein (PrP) Single protein molecule detection  
by glass nanopores
Synthetic Glass 
nanocapillary
Compared size distribution and translocation  
times of PrP with other model proteins
2013 [50]
Lysozyme Nanopore analysis of amyloid  
fibrils formed by lysozyme  
aggregation
Synthetic Glass nanocapil-
lary, low pH
Correlated the length of amyloid fibrils with  
residence times within a nanocapillary,  
verified results with simulations
2015 [51]
Amyloid-β (25–35, 35–25) Single-molecule study of initial structural 
features on the amyloidosis process
Biological α-Hemolysin Observed differences in conformation and  
aggregation rate of two identically sized peptides
2016 [52]
Lysozyme, avidin, and 
IgG
Influence of adsorption on  
proteins and amyloid detection  
by silicon nitride nanopore
Synthetic Silicon nitride, 
acid precleaning
In-depth analysis of the impact of adhesion on 
the dwell times of three amyloid-forming proteins. 
Correlation of blockades with monomer additions
2016 [53]
Amyloid-β (1–40) A novel device of array nanochannels 
integrated electrochemical detector  
for detection of amyloid β aggregation 
and inhibitor screening
Synthetic Nanochannel 
array, IR 
measurements
Used a parallel array of nanopores coated with Aβ 
to monitor the aggregation kinetics of Aβ in  
solution based on increased resistance
2016 [54]
α-Synuclein Intrinsic and membrane-facilitated 
α-synuclein oligomerization revealed  
by label-free detection through  
solid-state nanopores
Synthetic Silicon nitride, 
Tween20 coated
Measured the aggregation kinetics of α-Syn,  
determined four distinct oligomeric species,  
monitored aggregation in the presence  
of different lipid membranes
2016 [55]
Lysozyme, 
β-lactoglobulin, BSA
Detection of protein aggregate  
morphology through single  
antifouling nanopore
Synthetic Silicon nitride, 
PEG-coated
Used PEG-coated pore, and incorporated  
ellipsoidal shape analysis to estimate  
fibril lengths
2018 [56]
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processes.[50] In general, synthetic nanopores enable direct 
monitoring of changes in the populations of oligomeric spe-
cies and of large natively folded monomers (Figure 4). Recent 
years indicate a shift toward synthetic nanopores for amyloid 
sensing (Table 5), and we expect this trend to continue with the 
development of low-noise recording setups,[121] high-bandwidth 
recording equipment,[122] and advanced surface coating tech-
nologies[40,123] that may selectively bind amyloids. Because of 
their single-molecule sensitivity and broad size range, syn-
thetic nanopores may ultimately provide insight into the ways 
in which these amyloid-forming proteins aggregate, their size 
distributions, and their structures.
5. Challenges and Outlook
Given the development and commercialization success of 
nanopore-based DNA and RNA sequencing over the past 
20 years,[61,124–128] it is clear that resistive pulse sensing 
provides exciting opportunities as a bioanalytical method on 
the nanoscale. Applications of the technique to protein-based 
analytes, however, have not yet fully realized this potential. For 
example, one of the most compelling aspects of resistive pulse 
sensing—analyzing an individual resistive pulse to determine 
the physical characteristics of the unique particle that pro-
duced it—has yet to be fully exploited on amyloid targets. All 
of the work in Table 5 measured resistive pulses resulting from 
the translocations of single amyloid particles but performed 
subsequent analyses on populations of resistive pulses. Fur-
thermore, these studies typically reduced resistive pulses to two 
quantities, amplitude and dwell time, before clustering those 
data into groups to generate high-level comparisons about 
aggregation rates and distributions of aggregate sizes. These 
analyses produced insights into processes of amyloid aggrega-
tion and the size of aggregates, but they overlooked rich infor-
mation about relevant physical properties of individual amyloid 
particles such as shape, dipole moment, or conformational 
variability. In order to take full advantage of this detailed single-
amyloid information in a way that may have clinical usefulness, 
nanopore sensors must first overcome several challenges sum-
marized in Table 6.
Diagnostic characterization of a patient’s amyloid profile 
with nanopores requires investigation of complex biological 
solutions like blood or CSF. A fundamental challenge of 
applying label-free single-molecule techniques to such sam-
ples is the ability to discriminate between a few analytes of 
interest and a large concentration of background molecules. 
Purification techniques like filtration, size exclusion, or affinity 
chromatography can remove most of these background mol-
ecules, but they prolong analyses and add complications that 
can limit usefulness. For instance, the presence of interfaces as 
well as changes in pH or ionic strength during these procedures 
may influence the amyloid aggregation state in the sample. 
Direct analysis of complex samples without purification is pos-
sible when employing target-specific detection labels.[129] Amit 
Meller’s group simultaneously monitored optical and electrical 
signals of a strand of fluorescently labeled DNA transiting a 
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Table 6. Challenges of characterizing amyloid particles using nanopores, and potential solutions.
Specific challenges of characterizing amyloids with nanopores Potential solution(s) to challenges
General to all nanopore designs
– Distinguishing amyloid particles from other macromolecules in solution. – Amyloid-specific binders, combined with optical techniques.
– A range of nanopore diameters is necessary to characterize the entire range  
of amyloid species from monomer to fiber.
– Chambers engineered for parallel electrical recordings.
– Long protofibrils and mature fibrils may not enter the pore. – Increase size distribution of nanopores. Explore various nanopore shapes.
– High salt concentration of recording electrolytes affects aggregation kinetics  
of amyloid-forming peptides and proteins.
– Perform experiments at physiologic ion concentrations by reducing noise.
– Specialized technique that requires specialized instrumentation and expertise. – Automate technique in a commercial format.
– Removal of high-abundance proteins from sample without interfering with 
amyloid status.
– Employ separation techniques such as affinity pull-down before analysis.
Specific to biological nanopores
– Amyloid-forming proteins and, in particular, amyloid aggregates are too large to 
translocate through the biological nanopores that are currently available.
– Engineer larger biological nanopores.
– Capacitive current noise from bilayer capacitance, especially at high bandwidth. – Minimize membrane area.
– Fragility of lipid membranes to biological samples. – Separate chambers with a robust synthetic polymer instead of a lipid bilayer.
– Need to prepare lipid membrane before nanopore insertion. – Employ robust preformed membranes.
– Need to reconstitute biological pore into lipid membrane. – Preinsert biological nanopore and engineer pore to remain stable for long 
periods of time.
Specific to synthetic nanopores
– Strong, nonspecific interactions with the nanopore wall can lead to artifacts in the 
characterization of amyloids and to clogging of the pore.
– Generate surface coatings with desired properties.
– Large current noise at high bandwidth from electrical capacitance in silicon substrates. – Fabricate nanopores in glass (silica) or other substrates with low capacitance.
– Limited access to high-quality nanopores with desired characteristics like dimensions, 
geometry, surface chemistry, and amenity to surface coating.
– Improve fabrication and characterization methods for synthetic nanopores.
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nanopore,[130] and a similar approach may allow for selective 
resistive pulse analyses in complex protein samples. Optical 
methods can even replace electrical measurements to monitor 
ionic current through a nanopore, as has been shown with cal-
cium-flux sensing on nanopore arrays.[74,131–134] The challenge 
is, however, to collect a sufficient number of photons during 
the short-lived dwell times (µs) of proteins through nano-
pores. Solutions may emerge from sensing volumes them-
selves, as they can also be engineered to interact specifically 
with a target analyte. Binding sites designed inside or around 
biological nanopores enhance detection of target molecules 
through transient binding,[135] and synthetic nanopores with 
fluid lipid bilayer coatings can concentrate specific molecules 
around the surface of the pore by incorporating lipid anchors 
with binding sites into the coating.[40] But even when applying 
techniques to improve specificity, resistive pulse sensing with 
a single nanopore is still inherently a serial process and pro-
filing the individual molecules in a unpurified mixture may 
require long recording times. This limitation can be addressed 
through parallelization as shown by Oxford Nanopore Tech-
nologies with their recent nanopore-based DNA sequencing 
devices that record data from hundreds of nanopores indepen-
dently and simultaneously.[136] Meanwhile, novel integrated 
complementary metal-oxide-semiconductor (CMOS) current 
amplifiers combined with nanopore chips with low electrical 
capacitance will continue to improve the signal-to-noise ratio of 
high-bandwidth current recordings and provide more detailed 
and accurate insights from the translocations of single parti-
cles than the electrical setups currently available.[122] Fast and 
high-fidelity data acquisition requires robust data processing, 
and improvements in recording equipment have prompted a 
trend toward applying machine learning algorithms to resis-
tive pulse-based data, including deep learning by neural net-
works.[137,138] Amyloid characterization with nanopores will 
also benefit from further development and optimization of 
sensing volumes. While biological pores are currently limited 
to diameters less than 4 nm, engineered protein pores[102,103] 
as well as DNA origami channels[139] might extend the range 
of potential analyte sizes. Novel coating strategies taking inspi-
ration from nature[40,140] can overcome unwanted adhesion 
issues for synthetic pores, while fabrication techniques like 
dielectric breakdown[108] or laser-assisted nanopore forma-
tion[141] can quickly produce single-use pores without the need 
for sophisticated equipment.
Few, if any, techniques can quickly identify, quantify, and char-
acterize individual unlabeled proteins or protein aggregates in 
a complex aqueous sample.[142] Because nanopores can probe 
multiple physical parameters of individual particles in solution, 
we suggest that they are compelling candidates for an analytical 
platform technology that makes it possible to detect and char-
acterize amyloid aggregates. We hope that the studies summa-
rized here represent the initial steps toward a rapid and robust 
amyloid characterization platform using nanopores. If solutions 
to the challenges above can be incorporated into a single device, 
we propose that nanopore-based single particle analysis has the 
potential to improve the diagnosis of neurodegenerative diseases. 
Ultimately, nanopore-based amyloid characterization may enable 
monitoring of neurodegenerative disease progression using 
microliter volumes of patient samples in a rapid, low-cost, and 
broadly accessible format that can be applied routinely and longi-
tudinally to an ever growing and aging population. The insights 
gained from such population-based monitoring may help to accel-
erate the development of new therapies against those diseases.
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